

Dr. med. Christian Taverna kommentiert Myeloma Highlights vom ASH2016

Literatur:

- 1 [Michele Cavo, et al.](#) Intensification Therapy with Bortezomib-Melphalan-Prednison Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) Oral Abstract 6739; Session 731; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper91284.html>)
- 2 [Pieter Sonneveld, et al.](#) Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) Oral Abstract 242; Session 653; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper91988.html>)
- 3 [Thierry Facon, et al.](#) Final Analysis of Overall Survival from the First Trial. Oral Abstract 241; Session 653; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper91328.html>)
- 4 [Asher A. Chanan-Khan, et al.](#) Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor Poster Abstract 3313; Session 653; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper96799.html>)
- 5 [Philippe Moreau, et al.](#) Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux. Oral Abstract 489; Session 653; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper93492.html>)
- 6 [Christoph Driessen, et al.](#) The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVD) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13) Oral Abstract 487; Session 653; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper96473.html>)



Prof. Dr. med. Christoph Renner kommentiert Lymphoma Highlights vom ASH2016

- 1 [Wyndham H. Wilson, et al.](#) Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. Oral Abstract 469; Session 626; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper97112.html>)
- 2 [Steven H. Swerdlow, et al.](#) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016 127:2375-2390; doi: <https://doi.org/10.1182/blood-2016-01-643569>
- 3 [Umberto Vitolo, et al.](#) Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA). Oral Abstract 470; Session 626; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper96159.html>)
- 4 [Christiane Pott, et al.](#) Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. Oral Abstract 613; Session 623; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper96473.html>)
- 5 [Bruce D. Cheson, et al.](#) Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. Abstract 615; Session 623; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper91544.html>)
- 6 [Ramon Garcia-Sanz, et al.](#) Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Oral Abstract 1109; Session 624; ASH 2016 (<https://ash.confex.com/ash/2016/webprogram/Paper95020.html>)